CD1D and cancer: The reliance of PBMC-iNKT cells‘ cytotoxic recognition on antigen-presenting protein CD1d heavily restricts their efficacy; CD1d is limited to presenting glycolipid antigens, and multiple cancers downregulate CD1d expression to evade iNKT killing [42].